AEMD · XBRL financial data

Aethlon Medical financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (AEMD's year ends in late March)

In thousands of dollars	Q2 FY24Sep 30, 2023	Q3 FY24Dec 31, 2023	Q4 FY24Mar 31, 2024	Q1 FY25Jun 30, 2024	Q2 FY25Sep 30, 2024	Q3 FY25Dec 31, 2024	Q4 FY25Mar 31, 2025	Q1 FY26Jun 30, 2025	Q2 FY26Sep 30, 2025	Q3 FY26Dec 31, 2025	Q4 FY26Mar 31, 2026	Q1 FY27Jun 30, 2026
Revenue	—	—	year only	—	—	—	—	—	—	—	—	—
Revenue from contracts with customers	—	—	year only	—	—	—	—	—	—	—	—	—
Research and development	628	593	645*	415	261	240	1,328*	524	294	533	590*	549
General and administrative	851	979	765*	752	958	816	718*	735	521	742	698*	662
Total operating expenses	3,175	3,567	2,486*	2,621	2,902	1,815	2,004*	1,792	1,510	2,062	1,929*	1,579
Operating income (loss)	(3,175)	(3,567)	(2,486)*	(2,621)	(2,902)	(1,815)	(2,004)*	(1,792)	(1,510)	(2,062)	(1,929)*	(1,579)
Interest income	—	—	—	—	—	—	year only	—	—	—	year only	—
Interest expense	—	—	—	—	—	—	year only	—	—	—	year only	—
Other income (expense)	—	—	—	0	—	—	—	(6)	—	—	—	—
Income tax expense (benefit)	—	—	year only	—	—	—	year only	—	—	—	year only	—
Net income (loss)	(3,034)	(3,466)	(2,425)*	(2,571)	(2,807)	(1,755)	(6,255)*	(1,762)	(1,487)	(2,018)	(1,884)*	(1,548)
Earnings per share, basic USD per share	(1.22)	(1.37)	—	(0.34)	(0.20)	(0.13)	—	(0.85)	(3.74)	(2.45)	—	(4.02)
Earnings per share, diluted USD per share	(1.22)	(1.37)	—	(0.34)	(0.20)	(0.13)	—	(0.85)	(3.74)	(2.45)	—	(4.02)
Weighted average shares, basic thousands of shares	2,484	2,517	—	7,458	13,938	13,962	—	2,076	398	823	—	385
Weighted average shares, diluted thousands of shares	2,484	2,517	—	7,458	13,938	13,962	—	2,076	398	823	—	385

Fiscal quarters (AEMD's year ends in late March)

In thousands of dollars	Q2 FY24Sep 30, 2023	Q3 FY24Dec 31, 2023	Q4 FY24Mar 31, 2024	Q1 FY25Jun 30, 2024	Q2 FY25Sep 30, 2024	Q3 FY25Dec 31, 2024	Q4 FY25Mar 31, 2025	Q1 FY26Jun 30, 2025	Q2 FY26Sep 30, 2025	Q3 FY26Dec 31, 2025	Q4 FY26Mar 31, 2026	Q1 FY27Jun 30, 2026
Cash and cash equivalents	10,176	7,972	5,442	9,072	6,859	4,825	5,501	3,765	5,853	6,956	5,026	4,934
Prepaid and other current assets	311	277	506	478	279	88	449	277	182	185	332	283
Total current assets	10,487	8,249	6,226	9,550	7,138	4,968	5,950	4,051	6,254	7,142	5,570	5,611
Property and equipment, net	1,200	1,114	1,015	929	844	762	676	594	514	434	357	293
Right-of-use asset	1,019	951	883	814	744	673	602	530	456	383	308	232
Total assets	12,828	10,437	8,246	11,415	8,847	6,525	7,360	5,306	7,323	8,057	6,333	6,235
Accounts payable	685	693	778	1,068	923	611	535	571	571	469	385	411
Total current liabilities	1,711	2,101	1,830	2,129	2,331	1,774	1,899	1,627	1,405	1,257	1,447	1,036
Lease liability, non-current	798	725	650	574	497	418	337	255	172	87	0	—
Total liabilities	2,509	2,825	2,480	2,703	2,828	2,191	2,236	1,882	1,577	1,344	1,447	—
Accumulated deficit	(148,675)	(152,141)	(154,567)	(157,138)	(159,945)	(161,700)	(167,955)	(169,717)	(171,204)	(173,222)	(175,106)	(176,654)
Total stockholders' equity	10,319	7,611	5,766	8,713	6,019	4,334	5,124	3,424	5,746	6,713	4,886	5,199
Total liabilities and equity	12,828	10,437	8,246	11,415	8,847	6,525	7,360	5,306	7,323	8,057	6,333	6,235
Common shares outstanding (cover page) thousands of shares	2,493	2,620	13,900	13,937	13,962	14,457	2,585	2,599	761	1,315	2,371	711

Fiscal quarters (AEMD's year ends in late March)

In thousands of dollars	Q2 FY24Sep 30, 2023	Q3 FY24Dec 31, 2023	Q4 FY24Mar 31, 2024	Q1 FY25Jun 30, 2024	Q2 FY25Sep 30, 2024	Q3 FY25Dec 31, 2024	Q4 FY25Mar 31, 2025	Q1 FY26Jun 30, 2025	Q2 FY26Sep 30, 2025	Q3 FY26Dec 31, 2025	Q4 FY26Mar 31, 2026	Q1 FY27Jun 30, 2026
Net income (loss)	(3,034)	(3,466)	(2,425)*	(2,571)	(2,807)	(1,755)	(6,255)*	(1,762)	(1,487)	(2,018)	(1,884)*	(1,548)
Stock-based compensation	257	573	139*	139	113	90	72*	72	72	72	61*	50
Depreciation and amortization	91*	91*	86*	86	86*	84*	84*	83	80*	82*	80*	73
Net cash from operating activities	(2,704)*	(2,378)*	(2,565)*	(1,748)	(2,215)*	(2,011)*	(1,673)*	(1,715)	(1,659)*	(1,874)*	(1,750)*	(1,897)
Purchases of property and equipment	7*	9*	5*	0	0*	2*	(2)*	0	—	—	year only	9
Net cash from investing activities	(7)*	(9)*	(5)*	0	0*	(2)*	2*	0	—	—	(2)*	(9)
Proceeds from issuing common stock	0*	187*	50*	3,540	1,844*	0*	(1,844)*	0	3,744*	4,005*	(848)*	1,904
Net cash from financing activities	(10)*	177*	43*	5,379	(4)*	(7)*	2,359*	(5)	3,741*	2,983*	(196)*	1,817
Net change in cash	(2,722)*	(2,204)*	(2,530)*	3,630	(2,213)*	(2,034)*	686*	(1,736)	2,089*	1,103*	(1,930)*	(93)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Aethlon Medical	4,934	not reported	(1,897)	711,136	2.6 quarters	Q1 FY27 10-QJun 30, 2026
Family Office of America	637	533	149*	30.8M	—	Q2 FY26 10-QJun 30, 2026
Glucotrack	1,124	not reported	(3,616)*	10.6M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Odyssey Health	122	not reported	(160)*	110.2M	0.8 quarters	Q4 FY26 10-KJul 31, 2026
Autonomix Medical	3,460	0	(3,544)	971,043	1.0 quarters	Q1 FY27 10-QJun 30, 2026
Sonoma Pharmaceuticals	5,338	6,406	(649)	4.8M	8.2 quarters	Q1 FY27 10-QJun 30, 2026
Adm Tronics Unlimited	223	not reported	(33)	67.6M	6.8 quarters	Q1 FY26 10-QJun 30, 2026
Nuwellis	3,922	1,969	(3,175)*	3.6M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Bone Biologics	6,088	not reported	(532)*	3.4M	9.8 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.